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We have recently demonstrated that substitution of imidazoline moieties for the amidine groups of
pentamidine produces a molecule that is effective against rat Pneumocystis carinii pneumonia and that is
apparently less toxic than pentamidine. For this reason, 10 novel imidazoline substituted compounds were
evaluated for their effect against rat P. carinii pneumonia. While several of the new compounds were observed
to have advantages over pentamidine in the treatment of disease in the rat model, only one compound stood out
as a potential new clinical agent. Treatment for 2 weeks with intravenous (i.v.) doses of 1,3-di(4-imidazolino-
2-methoxyphenoxy)propane (DIMP) at 1 mg/kg per day produced an anti-P. carinii pneumonia effect
equivalent to i.v. doses of pentamidine at 10 mg/kg per day. Although pentamidine and one of the test drugs,
1,3-di(4-imidazolinophenoxy)propane, showed no activity against P. carinii pneumonia when administered per
os, DIMP exhibited potent anti-P. carinii pneumonia activity when given by daily gavage doses of 40 and 25
mg/kg. DIMP retained significant activity when given every other day by a gavage dose of 25 mg/kg. No toxicity
was observed with the drug at any of the dose levels or by either of the routes of administration. However, the
low solubility of the drug prevented testing at higher i.v. doses. Our conclusion is that DIMP has the potential
of providing a safer and more effective alternative to pentamidine for the treatment of P. carinii pneumonia.
Since the 1930s the aromatic diamidine compound penta-
midine has been known to be an effective agent for the
treatment of parasitic infections (6, 8). Although it was first
discovered to be efficacious against Pneumocystis carinji
pneumonia in 1958 (4), numerous side effects limited the use
of the drug against P. carinii pneumonia prior to the acquired
immunodeficiency syndrome (AIDS) epidemic. Because tri-
methoprim-sulfamethoxazole, the drug of choice for use in
patients with P. carinii pneumonia not associated with
AIDS, was found to cause a high frequency of adverse
reactions in the treatment of AIDS-related disease (3, 5), a
sharp increase was seen in the reliance on pentamidine for P.
carinii pneumonia therapy. Recent studies have shown that
the toxic side effects can be greatly decreased if the drug is
given by aerosol administration (7). Despite these encourag-
ing developments, there is still an urgent need for an
effective and nontoxic alternative drug that can be adminis-
tered per os or by the parental route for the treatment of P.
carinii pneumonia associated with AIDS. Recent observa-
tions by ourselves (8a) and others (10) demonstrated that
replacement of the amidine groups of pentamidine analogs
with imidazoline moieties results in compounds with in-
creased anti-P. carinii pneumonia activity and reduced tox-
icity. This discovery provided guidance in the search for new
anti-P. carinii pneumonia agents.
In the work described here, our on-going screening studies
for new therapeutic compounds against P. carinii pneumonia
(8a, 9) have been extended to include a series of 10 novel
imidazoline-substituted compounds. These compounds were
examined for their ability to reduce the mean histologic lung
scores in P. carinii-infected rats when the compounds were
administered intravenously (i.v.). Two compounds chosen
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from this study and a promising new derivative of pentami-
dine (butamidine) taken from a previous screening study (8a)
were examined for their effects against P. carinii pneumonia
in dose-response experiments. In addition, two compounds
were tested for their therapeutic effects against P. carinii
pneumonia when administration of the drug was per os.
MATERIALS AND METHODS
Pentamidine analogs. All of the compounds tested in this
study were synthesized as the mono- or dihydrochloride
salts in our laboratory by previously described methods (2).
The purity of each drug was determined by high-perfor-
mance liquid chromatography, elemental analysis, and pro-
ton magnetic resonance. Structures of the imidazoline deriv-
atives are shown in Fig. 1 and Table 1, and the melting points
and elemental analyses for the novel compounds are given in
Table 2.
Animal protocol. The induction and treatment of P. carinii
pneumonia was carried out with only minor alterations to
previously published methods (1, 9, 10), in the following
manner. Male Sprague-Dawley rats (weight, 150 to 200 g)
that were barrier raised and not certified to be virus-free
were obtained from Hilltop Laboratories (Scottsdale, Pa.).
The individually caged animals were begun on a low-protein
(8%) diet (ICN Biomedicals, Cincinnati, Ohio) and drinking
water containing tetracycline (0.5 mg/ml) and dexametha-
sone (1.0 ,ug/ml) immediately upon arrival in the laboratory.
This regimen was continued for the next 8 weeks, with fluid
intake monitored daily and animals weighed weekly. At the
beginning of week 6, animals were divided into groups of
eight or more animals per group and the test compounds
were administered by one of the following protocols: (i) i.v.
injection at a daily dose of 10 mg/kg or the next highest
soluble, nontoxic dose for 14 days, (ii) oral administration by
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FIG. 1. Structures of pentamidine analogs.
gavage daily for 14 days, or (iii) oral administration by
gavage every other day for 14 days. Saline- and pentamidine-
treated groups were included as negative and positive con-
trols, respectively.
Assessment of the drugs against P. carinii pneumonia.
Animals were sacrificed at the end of week 8 by chloroform
inhalation. The right lung was inflated in situ with 10%
Formalin and fixed for histologic examination. The lung
tissue was sectioned longitudinally and stained with Grocott
methenamine silver stain. The Grocott methenamine silver
stain selectively stains the walls of the P. carinii cysts.
Stained sections were coded, and each section was scored
by two examiners using a blinded protocol. Sections were
read and scored by the following system: 0.5, less than 10
cysts counted per two fully examined sections; 1, scattered
cysts with less than 10% of lung tissue involved; 2, scattered
cysts with limited intense focal involvement and 10 to 25% of
lung tissue involved; 3, scattered cysts with numerous
intense areas of focal involvement and 26 to 50% of lung
tissue involved; 4, cysts found throughout the tissue with
numerous very intense focal areas of involvement having
greater than 50o of lung tissue involved.
Evaluation of toxicity. Toxicities of the test compounds
were evaluated at concentrations of 10 mg/kg or the next
highest soluble or nontoxic dose by the following criteria: 0,
no local, clinical, or histologic toxicity; +, all animals
survived the test dose without observable distress, minimal
or no signs of hypotension were observed, some excess
weight loss and/or mild signs of local toxicity at the injection
site were noted, and no histopathology was noted; + +, all or
most animals survived the test dose with marked signs of
hypotension, all animals were observed to have other clini-
cal side effects and/or some histopathology, and many ani-
mals had severe lesions at the injection site; + + +, an acute
toxic effect was seen after a single dose with symptoms
compatible with severe hypotension and/or a sharp decrease
TABLE 1. Structures of imidazoline derivatives of pentamidine and their activities against P. carinii pneumonia
x x
N 4X~~~0-(CH2)n0°44.j 3 2 CO
N-'-R R_-N
Structure component No. of animals with the following MeanCompound Position of histologic scores': hsooi oiiy
no. imidazoline
n X R 0.5 1 2 3 4 score
Saline 1 2 14 41 58 3.3 0
Pentamidine 27 36 19 5 0 1.2 + +
1 3 -H -H 4 7 0 0 0 0 0.5 0
2 3 -H -H 3 1 2 4 3 0 2.0 0
3c 3 -OCH3 -H 4 8 5 2 0 0 0.9 od
4e 3 -OCH3 -H 3 7 3 0 0 0 0.7 +++
5 4 -H -H 4 1 2 3 1 0 1.6 +
6c 4 -H -H 3 0 0 1 4 5 3.4 +
7c 4 -OCH3 -H 4 0 2 2 1 1 2.2 od
8c 4 -H -CH3 4 0 1 1 3 3 3.0 ++++
9 5 -H -H 4 5 3 0 0 0 0.7 0
ioe 5 -OCH3 -H 4 1 3 1 2 0 1.6 +++
llc 5 -H -CH3 4 0 0 2 4 2 3.0 ++++
a Activity was tested at 10 mg/kg unless noted otherwise.
b Toxicity was tested at 10 mg/kg or the highest soluble dose. See the text for an explanation of the symbols.
c Tested at 2.5 mg/kg.
d Toxicity was determined at 2.5 mg/kg.
e Tested at 5.0 mg/kg.
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TABLE 2. Physical data of novel imidazoline derivatives of pentamidine
Compound FouaMelting Elemental analysis (calculated/found []
no. Formula point (°C)' C H N
1 C21H24N402 2HCl 2H20 Dec at 106 49.47/49.21 6.13/6.28 10.99/10.80
2 C2jH24N402 2HC1 1.9H20 119-139 53.48/53.51 6.37/6.34 11.88/11.81
3 C23H28N404 1.75HCl 2H20 252 52.69/52.59 6.49/6.38 10.60/10.46
4 C23H28N404 2HCl 2.2H20 253-255 51.44/51.49 6.46/6.54 10.43/10.29
5 C22H26N402 2HCl * 2.2H20 249-250 53.81/53.80 6.65/6.70 11.41/11.36
6 C22H26N402 2HC1 * 2H20 >300 54.21/53.83 6.62/6.65 11.49/11.31
7 C24H3ON404* 2HC1 2H20 Dec at 268 52.65/52.76 6.63/6.42 10.23/10.15
8 C24H30N402. 1HCl 1.5H20 203-205 61.33/61.17 7.29/7.40 11.92/11.75
10 C25H32N404 2HCl 2.5H20 175 52.63/52.47 6.89/6.85 9.82/9.97
11 C25H32N402 2HCl 1H20 203-204 58.71/58.73 7.09/7.16 10.95/10.88
a Dec, Decomposes.
in the animals' health status after multiple doses, and death
occurred in less than 50% of the animals, resulting in a
reduced screening dose; and ++++, death occurred in
greater than 50% of the animals with a resulting reduction in
screening dose.
Statistical studies. Student's t test was used to calculate the
P values of each test group when it was compared with the
saline-treated and pentamidine-treated groups. The statisti-
cal analysis was carried out by using a software package
(StatView 512+; Brainpower, Inc., Calabasas, Calif.) on a
personal computer (Macintosh II; Apple Computers).
RESULTS AND DISCUSSION
Structure-activity studies. Compound structures, activities
against P. carinii pneumonia when administered i.v., and
toxicities of the 11 diimidazoline-substituted molecules are
given in Table 1. The activities and toxicities of the test
compounds were compared with those of the pentamidine-
and saline-dosed control groups. In general, variation of the
central alkyl bridge of from three through five carbons
demonstrated that the compounds with an odd number of
carbons in the central link produced lower mean histologic
scores in the P. carinii-infected rats. The mean histologic
scores produced by daily i.v. injections of the three- and
five-carbon-chain-unsubstituted compounds (compounds 1
and 9) were 0.5 and 0.7, respectively, while dosing with the
corresponding four-carbon compound (compound 5) gave a
score of 1.6. Unfortunately, direct comparisons between
activity and chain length variation were not possible in the
methoxy-substituted compounds (compounds 3, 7, and 10)
TABLE 3. Dose-response activity of butamidine versus that of
pentamidine against P. carinii pneumonia by daily i.v. injection
No. of animals with
Dose the following Mean
Compound (mg/kg histologic scores: histologic Toxicitya
per day) score
0.5 1 2 3 4
Saline 0 0 2 5 5 3.3 0
Pentamidine 10.0 3 5 2 1 0 1.2 ++
1.0 1 0 3 5 3 2.8 0
0.1 0 0 0 7 5 3.4 0
Butamidine 10.0 10 2 0 0 0 0.6 0
1.0 0 1 3 5 3 2.8 0
0.1 0 0 4 5 2 2.8 0
a See the text for an explanation of the symbols.
or derivatives with imidazoline groups in the 3 position
(compounds 2 and 6). This circumstance was the result of the
necessity of using reduced screening doses of some of the
compounds because of either their high toxicities or low
solubilities in saline.
The addition of methoxy groups on the aromatic ring in the
position meta to the imidazoline moiety (compounds 3, 7,
and 10) gave compounds that appeared to be more active,
less soluble, and more toxic than the corresponding unsub-
stituted analogs. However, statistical comparisons were not
possible because of differences in dosing levels. One com-
pound (compound 3) in this series proved to be especially
interesting. Compound 3 gave a mean histologic score of 0.9
at a relatively low daily dose of 2.5 mg/kg. Although no
toxicity was observed at this dose, toxicity could not be
evaluated at higher i.v. doses because of the low solubility of
the compound. The result of moving the imidazoline moiety
from the position para to the ether bridge to the meta
position could only be ascertained with the three-carbon-
chain analogs (compounds 1 and 2). In this case, the deriv-
ative with the imidazoline group in the para position (com-
pound 1) proved to be significantly more active (P = 0.001)
than the corresponding meta-substituted compound (com-
pound 2). Substitution of a methoxy group para to the
imidazoline moiety (compound 4) appeared to increase the
TABLE 4. Dose-response activity of DIPP versus that
of pentamidine against P. carinii pneumonia by
daily i.v. or oral administration
No. of animals with
Dose the following Mean
Compound (mg/kg histologic scores: histologic Toxicity'
per day) score
0.5 1 2 3 4
Saline' 0 0 4 14 24 3.5 0
Pentamidine' 10.0 6 13 8 1 0 1.3 ++
5.0 1 3 7 1 0 1.7 0
1.0 1 0 3 5 3 2.8 0
0.1 0 0 0 7 5 3.4 0
DIPPb 10.0 7 0 0 0 0 0.5 0
5.0 2 5 3 0 0 1.2 0
1.0 0 0 4 4 2 2.8 0
0.25 0 1 1 5 3 3.0 0
DIPPC 20.0 0 1 1 6 2 2.9 0
a See the text for an explanation of the symbols.
b Administered i.v.
c Administered orally.
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TABLE 5. Dose-response activity of DIMP against P. carinii
pneumonia by daily i.v. administration
No. of animals with
Dose the following Mean
Compound (mg/kg histologic scores: histologic Toxicitya
per day) scores
0.5 1 2 3 4
Saline 0 0 1 4 3 3.3 0
DIMP 2.5 6 3 2 0 0 0.9 0
1.0 3 6 3 0 0 1.1 0
0.5 1 2 7 2 0 1.9 0
0.25 0 1 2 4 4 3.0 0
a See the text.
activity and toxicity of compound 4 relative to those of the
unsubstituted analog (compound 2).
Finally, placement of a methyl group on an imidazoline
nitrogen (compounds 8 and 11) produced highly toxic com-
pounds that showed no activity at the highest nontoxic
dose.
Dose-response of butamidine. A comparison of the dose-
response data of 1,4-di(4-amidinophenoxy)butane (butami-
dine) and pentamidine is presented in Table 3. At the highest
daily dose level evaluated in the dose-response experiment,
10 mg of butamidine per kg was found to be effective (P <
0.001) when compared with saline controls and significantly
more potent (P = 0.002) and less toxic than pentamidine.
However, reduction of the daily dose of butamidine to 1
mg/kg resulted in the loss of the drug's anti-P. carinji
pneumonia properties. A corresponding reduction of the
pentamidine dose resulted in a similar loss in activity. Close
examination of the data in Table 3 reveals that the dose-
response curves for pentamidine and butamidine are very
similar.
Dose-response studies of DIPP. Table 4 outlines the dose-
response studies with 1,3-di(4-imidazolinophenoxy)propane
(DIPP). DIPP was significantly more effective than pentami-
dine (P = 0.001) in reducing the mean histologic score of P.
carinii-infected rats with a daily i.v. dose of 10 mg/kg. As
with pentamidine, the anti-P. carinii pneumonia activity of
DIPP was greatly reduced and not statistically significantly
different from that in saline-treated controls when given at a
daily i.v. dose of 1.0 mg/kg. Both DIPP and pentamidine
were observed to retain some activity against P. carinji
pneumonia in rats when the daily i.v. dose was 5 mg/kg. The
drug was found to be inactive against P. carinii pneumonia
when given by gavage at 20 mg/kg per day.
Dose-response studies of DIMP. The data from the dose-
response experiments for i.v. administration of 1,3-di(4-
imidazolino-2-methoxyphenoxy)propane (DIMP) are given
in Table 5. The data for administration of the drug per os are
given in Table 6. Because of the low solubility of the drug,
the highest dose administered by the i.v. route in the
dose-response study was 2.5 mg/kg. The mean histologic
score achieved by this dose was 0.9. The dose-response
study revealed that DIMP was only slightly less active when
administered at 1.0 mg/kg per day and that the anti-P. carinji
pneumonia effect remained significant (P < 0.001) down to a
daily dose of 0.5 mg/kg. Activity against P. carinii pneumo-
nia was not significant when the daily i.v. dosage was
reduced to 0.25 mg/kg. In addition to the potent activity seen
with i.v. injection, DIMP was found to be highly active when
it was administered by gavage at daily doses of 40 and 25
mg/kg (Table 6). No drug toxicity was observed at the
TABLE 6. Dose-response activity of DIMP against P. carinji
pneumonia by oral administration daily or every other day
No. of animals with
Dosing time and Dose the following Mean
compound (mg/kg) histologic scores: histologic Toxicityascores
0.5 1 2 3 4
Daily
Saline 1 0 10 9 9 2.9 0
DIMP 40.0 4 6 1 0 0 0.9 0
25.0 4 8 3 1 0 1.2 0
10.0 0 6 7 5 1 2.1 0
Every other day
Saline 0 0 3 4 9 3.4 0
Pentamidine 10.0 0 1 1 4 10 3.4 0
DIMP 25.0 1 7 3 4 1 1.8 0
10.0 0 3 8 3 2 2.3 0
a See the text.
highest gavage dose. Surprisingly, DIMP was observed to be
nearly as active when it was administered per os at 25 mg/kg
every other day for 2 weeks (Table 6).
In summary, our initial screening studies indicated that
three compounds, the diamidine, butamidine, and the two
diimidazolines, DIPP and DIMP, appear to be more effective
and less toxic than pentamidine in the rat model of P. carinji
pneumonia. The dose-response studies revealed, however,
that the anti-P. carinii pneumonia activity of butamidine and
DIPP were greatly reduced when drug dosage was decreased
10-fold. In contrast, DIMP given i.v. daily at 1 mg/kg
produced an anti-P. carinii pneumonia effect equivalent to
that of pentamidine given at 10 mg/kg per day. Significant
activity remained when DIMP was given i.v. at 0.5 mg/kg per
day. Furthermore, DIMP was highly effective when it was
given orally, even when it was administered on an alternate-
day dosing schedule. No toxicity was observed at any of the
i.v. or oral doses used. Thus, the diimidazoline compound
DIMP appears to be safer and more effective than pentami-
dine in the rat model and warrants further detailed investi-
gations to explore its future as an alternative drug for the
treatment of P. carinii pneumonia.
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